These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 25006968)

  • 21. Ezogabine (Potiga) toxicity.
    Med Lett Drugs Ther; 2013 Nov; 55(1430):96. PubMed ID: 24276503
    [No Abstract]   [Full Text] [Related]  

  • 22. Ezogabine (Potiga) for epilepsy.
    Med Lett Drugs Ther; 2012 Aug; 54(1397):65-7. PubMed ID: 22907178
    [No Abstract]   [Full Text] [Related]  

  • 23. Ezogabine: a novel antiepileptic for adjunctive treatment of partial-onset seizures.
    Amabile CM; Vasudevan A
    Pharmacotherapy; 2013 Feb; 33(2):187-94. PubMed ID: 23386597
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The effects of ethanol on the pharmacokinetics, pharmacodynamics, safety, and tolerability of ezogabine (retigabine).
    Crean CS; Tompson DJ
    Clin Ther; 2013 Jan; 35(1):87-93. PubMed ID: 23328270
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Retigabine: fewer drug interactions.
    Prescrire Int; 2012 Mar; 21(125):61. PubMed ID: 22428181
    [TBL] [Abstract][Full Text] [Related]  

  • 26. An Investigation into Retigabine (Ezogabine) Associated Dyspigmentation in Rat Eyes by MALDI Imaging Mass Spectrometry.
    Groseclose MR; Castellino S
    Chem Res Toxicol; 2019 Feb; 32(2):294-303. PubMed ID: 30638013
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ezogabine skin discoloration is reversible after discontinuation.
    Mathias SV; Abou-Khalil BW
    Epilepsy Behav Case Rep; 2017; 7():61-63. PubMed ID: 28417066
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Retigabine as adjunctive therapy in adults with partial-onset seizures: integrated analysis of three pivotal controlled trials.
    Porter RJ; Burdette DE; Gil-Nagel A; Hall ST; White R; Shaikh S; DeRossett SE
    Epilepsy Res; 2012 Aug; 101(1-2):103-12. PubMed ID: 22512894
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ring chromosome 20: a pediatric potassium channelopathy responsive to treatment with ezogabine.
    Walleigh DJ; Legido A; Valencia I
    Pediatr Neurol; 2013 Nov; 49(5):368-9. PubMed ID: 23916860
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A novel design for a dose finding, safety, and drug interaction study of an antiepileptic drug (retigabine) in early clinical development.
    Sachdeo R; Partiot A; Biton V; Rosenfeld WE; Nohria V; Tompson D; DeRossett S; Porter RJ
    Int J Clin Pharmacol Ther; 2014 Jun; 52(6):509-18. PubMed ID: 24755135
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Retigabine for partial onset seizures.
    Rheims S; Ryvlin P
    Expert Rev Neurother; 2012 May; 12(5):509-17. PubMed ID: 22550979
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ezogabine: development and role in the management of epileptic seizures.
    Verma A; Kumar R; Kumar M
    Mini Rev Med Chem; 2013 Apr; 13(5):697-705. PubMed ID: 22931529
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The effect of ezogabine on the pharmacokinetics of an oral contraceptive agent.
    Crean CS; Tompson DJ; Buraglio M
    Int J Clin Pharmacol Ther; 2013 Nov; 51(11):847-53. PubMed ID: 24040852
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of hemodialysis on pharmacokinetics of ezogabine/retigabine and its N-acetyl metabolite in patients with end stage renal disease.
    Tompson DJ; Buraglio M; Bullman J; Crean CS; Rayner K
    Curr Clin Pharmacol; 2014; 9(4):319-25. PubMed ID: 25387761
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy of retigabine in adjunctive treatment of partial onset seizures in adults.
    Splinter MY
    J Cent Nerv Syst Dis; 2013 Oct; 5():31-41. PubMed ID: 24250245
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Retigabine/Ezogabine, a KCNQ/K(V)7 channel opener: pharmacological and clinical data.
    Orhan G; Wuttke TV; Nies AT; Schwab M; Lerche H
    Expert Opin Pharmacother; 2012 Aug; 13(12):1807-16. PubMed ID: 22783830
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The preclinical discovery and development of ezogabine for the treatment of epilepsy.
    Jankovic S; Ilickovic I
    Expert Opin Drug Discov; 2013 Nov; 8(11):1429-37. PubMed ID: 24053653
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ezogabine (retigabine).
    Stafstrom CE; Grippon S; Kirkpatrick P
    Nat Rev Drug Discov; 2011 Sep; 10(10):729-30. PubMed ID: 21959281
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The mechanism of action of retigabine (ezogabine), a first-in-class K+ channel opener for the treatment of epilepsy.
    Gunthorpe MJ; Large CH; Sankar R
    Epilepsia; 2012 Mar; 53(3):412-24. PubMed ID: 22220513
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical utility, safety, and tolerability of ezogabine (retigabine) in the treatment of epilepsy.
    Ciliberto MA; Weisenberg JL; Wong M
    Drug Healthc Patient Saf; 2012; 4():81-6. PubMed ID: 22888276
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.